Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G I Shapiro

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancerG I Shapiro, J G Supko, A Patterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumorsB Markman, J Tabernero, I Krop, et al.
British Journal of Cancer|March 21, 2013
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding studyM D Michaelson, A X Zhu, D P Ryan, et al.
Oncogene|February 2, 1999
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motilityR Salgia, J L Li, D S Ewaniuk, et al.
Oncogene|April 15, 2008
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsD Li, L Ambrogio, T Shimamura, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1997
Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumorsD J Marsh, Z Zheng, A Arnold, et al.
ESMO Open|August 29, 2022
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket studyV Boni, B Pistilli, I Braña, et al.
ESMO Open|April 9, 2025
Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphomaU M Lauer, A Awada, S Postel-Vinay, et al.
ESMO Open|September 9, 2022
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumorsH Park, G I Shapiro, X Gao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumoursD S Boss, G K Schwartz, M R Middleton, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancerG I Shapiro, J G Supko, A Patterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumorsB Markman, J Tabernero, I Krop, et al.
British Journal of Cancer|March 21, 2013
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding studyM D Michaelson, A X Zhu, D P Ryan, et al.
Oncogene|February 2, 1999
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motilityR Salgia, J L Li, D S Ewaniuk, et al.
Oncogene|April 15, 2008
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsD Li, L Ambrogio, T Shimamura, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1997
Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumorsD J Marsh, Z Zheng, A Arnold, et al.
ESMO Open|August 29, 2022
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket studyV Boni, B Pistilli, I Braña, et al.
ESMO Open|April 9, 2025
Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphomaU M Lauer, A Awada, S Postel-Vinay, et al.
ESMO Open|September 9, 2022
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumorsH Park, G I Shapiro, X Gao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumoursD S Boss, G K Schwartz, M R Middleton, et al.
Pageof 3